[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626381":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":61,"centralContacts":65,"locations":71,"responsibleParty":89,"collaborators":93,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":44,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":44,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":73,"whyStopped":44,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University of Kentucky","OTHER",[8,15,21,26,30,34],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo CBD\u002FPlacebo Inhaled Cannabis","PLACEBO_COMPARATOR","Participants will receive non-therapeutic, experimental doses of placebo\u002Finactive cannabidiol in combination with non-therapeutic, placebo\u002Finactive vaporized marijuana. Inactive cannabidiol and inactive marijuana will be administered once per session. It is possible to receive both inactive drugs on the same day.\n\nInactive\u002FPlacebo Cannabidiol: Placebo\u002Finactive cannabidiol will be administered orally.\n\nInactive\u002FPlacebo: Experimental, non-therapeutic administration of an inactive\u002Fplacebo marijuana dose will be administered through a vaporizer.",[13,14],"Drug: Placebo Cannabidiol","Drug: Placebo Inhaled Cannabis",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo CBD\u002FActive Inhaled Cannabis","EXPERIMENTAL","Participants will receive a non-therapeutic, experimental dose of inactive\u002Fplacebo cannabidiol in combination with non-therapeutic, active vaporized marijuana. It is possible to receive inactive cannabidiol and active marijuana on the same day.\n\nInactive\u002FPlacebo Cannabidiol: Active cannabidiol will be administered orally.\n\nActive Marijuana: Experimental, non-therapeutic administration of an active marijuana dose will be administered through a vaporizer.",[20,13],"Drug: Active Inhaled Cannabis",{"label":22,"type":17,"description":23,"interventionNames":24},"CBD (Medium Dose)\u002FPlacebo Inhaled Cannabis","Participants will receive a non-therapeutic, experimental dose of active cannabidiol in combination with non-therapeutic, inactive vaporized marijuana. It is possible to receive active cannabidiol, and inactive marijuana on the same day.\n\nActive Cannabidiol: Active cannabidiol will be administered orally.\n\nInactive\u002FPlacebo Marijuana: Experimental, non-therapeutic administration of an inactive\u002Fplacebo marijuana dose will be administered through a vaporizer.",[25,14],"Drug: Cannabidiol, Medium Dose",{"label":27,"type":17,"description":28,"interventionNames":29},"CBD (Medium Dose)\u002FActive Inhaled Cannabis","Participants will receive non-therapeutic, experimental doses of active cannabidiol in combination with non-therapeutic, experimental doses of active vaporized marijuana. Cannabidiol and marijuana doses will be administered once during each session. It is possible to receive both active drugs on the same day.\n\nVaporized Marijuana: Active Marijuana administered through a vaporizer\n\nCannabidiol: Active cannabidiol will be administered orally",[25,20],{"label":31,"type":17,"description":23,"interventionNames":32},"CBD (Higher Dose)\u002FPlacebo Inhaled Cannabis",[33,14],"Drug: Cannabidiol, Higher Dose",{"label":35,"type":17,"description":36,"interventionNames":37},"CBD (Higher Dose)\u002FActive Inhaled Cannabis","Participants will receive non-therapeutic, experimental doses of active cannabidiol in combination with a non-therapeutic, experimental dose of active vaporized marijuana. Active cannabidiol and marijuana doses will be administered once during each session. It is possible to receive both active drugs on the same day.\n\nActive Cannabidiol: Active cannabidiol will be administered orally.\n\nActive Marijuana: Active Marijuana will be administered through a vaporizer.",[33,20],[39,45,49,53,57],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"DRUG","Cannabidiol, Medium Dose","Active Cannabidiol: Active cannabidiol (medium dose) will be administered orally for 14 days.",[27,22],null,{"type":40,"name":46,"description":47,"armGroupLabels":48,"otherNames":44},"Cannabidiol, Higher Dose","Description: Active Cannabidiol: Active cannabidiol (higher dose) will be administered orally for 14 days.",[35,31],{"type":40,"name":50,"description":51,"armGroupLabels":52,"otherNames":44},"Active Inhaled Cannabis","Active Marijuana: Active Marijuana (active inhaled cannabis) will be administered through a vaporizer once per study session day (Day 1, 7, 14) per block (3 blocks total).",[35,27,16],{"type":40,"name":54,"description":55,"armGroupLabels":56,"otherNames":44},"Placebo Cannabidiol","Inactive\u002FPlacebo Cannabidiol: Inactive\u002Fplacebo cannabidiol will be administered orally for 14 days.",[16,9],{"type":40,"name":58,"description":59,"armGroupLabels":60,"otherNames":44},"Placebo Inhaled Cannabis","Inactive\u002FPlacebo Marijuana: Experimental, non-therapeutic administration of an inactive\u002Fplacebo marijuana dose will be administered through a vaporizer at each study session day (Days 1, 7, 14) per block (3 blocks total).",[31,22,9],[62],{"name":63,"affiliation":5,"role":64},"Hannah M Harris, Ph.D.","PRINCIPAL_INVESTIGATOR",[66],{"name":67,"role":68,"phone":69,"phoneExt":44,"email":70},"Paul A Nuzzo, M.A.","CONTACT","859-323-0002","pnuzz2@email.uky.edu",[72],{"facility":5,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"RECRUITING","Lexington","Kentucky","40508","United States","US",{"type":80,"coordinates":81},"Point",[82,83],-84.47772,37.98869,{"lat":83,"lon":82},[86,87],{"name":67,"role":68,"phone":69,"phoneExt":44,"email":70},{"name":63,"role":68,"phone":44,"phoneExt":44,"email":88},"hannah.harris@uky.edu",{"type":90,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"SPONSOR_INVESTIGATOR","Hannah Harris","Assistant Professor",[94],{"name":95,"class":96},"National Institute on Drug Abuse (NIDA)","NIH","100626381","early-phase-1-repeated-cbd-administration-and-cannabis-outcomes-100626381",false,"NCT07434895","Repeated CBD Administration and Cannabis Outcomes","The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study","Inclusion Criteria:\n\n* English-speaking, literate adults,\n* Male or female,\n* Between the ages of 18-55,\n* Body Mass Index from 18.5-32.0 kg\u002Fm2,\n* Not currently seeking treatment for cannabis or drug use,\n* Able to provide written informed consent and perform all study procedures,\n* If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),\n* Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and\n* Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries.\n\nExclusion Criteria:\n\n* Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and\u002For alcohol that would require medical management,\n* Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\]),\n* Current or past history of major psychiatric disorder that would limit ability to participate in the study,\n* Use of cannabis exclusively for medical reasons (no recreational use reported),\n* Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),\n* Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,\n* Clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist),\n* Clinically significant abnormal laboratory findings,\n* History of seizure disorder,\n* Clinically significant history of head injuries requiring medical management or long lasting sequalae, and\n* Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice).",true,"ALL","18 Years","55 Years",{"count":109,"type":110},23,"ESTIMATED","INTERVENTIONAL",[113],"EARLY_PHASE1","This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.",[116,117,118],"Cannabis","Abuse Liability","Experimental Pain in Healthy Human Participants",[120,121,122],"marijuana","cannabidiol (CBD)","marijuana users","2026-06-08",{"date":125,"type":126},"2026-06-10","ACTUAL",{"date":128,"type":110},"2026-06-29",{"date":130,"type":110},"2029-12-01",{"name":91,"class":6},1]